Clinical Studies In Japan Today: Another Look At The World's Second-Largest Prescription Drug Market In A Post-Pandemic World

The pharma industry has compelling reasons to include Japan in clinical trials and the country's responses to the COVID-19 pandemic have only furthered the country's appeal to the rest of the pharma industry. Japan's large patient population, mature local market and flexible data regulations for clinical trials are just a few reasons to involve Japan in global studies. To become more attractive to global sponsors, Japan has undergone sweeping changes to create a climate conducive to clinical development programs by aligning drug approval timelines with those of the US and Europe.

Key takeaways include:

• Recent efforts to reduce regulatory issues in Japan
• The challenges and developments in patient recruitment and engagement
• Considerations for site selection and site management
• Customizing decentralized clinical trials and the future of hybrid trials in Japan